Lower-extremity growth patterns and skeletal maturation in children with unilateral fibular hemimelia

2018 ◽  
Vol 49 (1) ◽  
pp. 122-127 ◽  
Author(s):  
Andy Tsai ◽  
Paul K. Kleinman ◽  
Tal Laor ◽  
James R. Kasser
Author(s):  
Paul A. Boepple ◽  
M. Joan Mansfield ◽  
John D. Crawford ◽  
John F. Crigler ◽  
Kathleen Link ◽  
...  

PEDIATRICS ◽  
1965 ◽  
Vol 36 (5) ◽  
pp. 721-731
Author(s):  
W. W. Sutow ◽  
R. A. Conard ◽  
K. M. Griffith

Longitudinal studies on 38 children who were exposed to fallout radiation on Rongelap and Ailingnae atolls, Marshall Islands, in March, 1954, have shown retardation in both statural growth and skeletal maturation among the exposed boys as compared to non-exposed comparison children. The retardation was noted among boys who were under 5 years of age when exposed to the fallout, being most prominent among those who were 12 to 18 months old at time of exposure. No statistically significant differences were noted in the growth patterns between the exposed and the non-exposed group of girls and between 39 children born to exposed parents subsequent to fall-out and 53 children born to non-exposed parents.


1989 ◽  
Vol 79 (9) ◽  
pp. 421-431 ◽  
Author(s):  
ML Zivot ◽  
IO Kanat

Malignant melanoma, the leading cause of death from disease of the skin, often is found on the lower extremity. A thorough understanding of the disease entity is essential, because misdiagnosis or delayed diagnosis can be fatal. In Part I of this two-part clinical and surgical review of malignant melanoma, the authors discussed etiology, risk factors, signs, symptoms, clinical features, and growth patterns. Part II places special emphasis on diagnosing malignant melanoma and differentiating it from other lesions of the lower extremity. Clinical staging of the tumor and the corresponding surgical criteria are presented from a podiatric medical standpoint.


1989 ◽  
Vol 79 (8) ◽  
pp. 367-374 ◽  
Author(s):  
ML Zivot ◽  
IO Kanat

Malignant melanoma, the leading cause of death from diseases of the skin, often is found on the lower extremity. When encountered by the podiatric physician, a thorough understanding of the disease entity is essential, as misdiagnosis or delayed diagnosis can have fatal consequences. The authors present the first of a two-part comprehensive clinical and surgical review of malignant melanoma. Part I reviews etiology, risk factors, signs, symptoms, clinical features, and growth patterns. In Part II, a pictorial lower extremity differential diagnosis will be provided, along with diagnostic and surgical criteria for the podiatric surgeon.


2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. A140-A141
Author(s):  
Kanwal Anwar ◽  
Ipek Alpertugna ◽  
Danielle Detelich ◽  
Konstantin Balonov ◽  
Michael Tarnoff ◽  
...  

Abstract A 76-year-old woman presented with worsening fasting hyperglycemia on routine blood sugar measurement, previously well-controlled on Metformin, requiring initiation of insulin. Her medical history included type 2 diabetes mellitus, hypertension, and aortic stenosis. Over the next few weeks, she developed bilateral upper and lower extremity proximal muscle weakness, episodes of confusion, rapid weight loss and increasing lower extremity edema. She did not have typical Cushingoid features of moon facies, easy bruising, centripetal obesity, abdominal striae, dorsocervical fat padding, or hyperpigmentation. Laboratory data revealed severe hypokalemia, elevated cortisol of 138 (3.7–19.4 ug/dL) and ACTH of 368 (6–50 pg/mL) consistent with ACTH-dependent Cushing’s syndrome. She was hospitalized for emergent therapy with etomidate infusion, potassium supplementation, and started on spironolactone. 24-hour urinary analysis demonstrated elevated catecholamines and metanephrines: epinephrine 552 (2–16 mcg/g cr), norepinephrine 1881 (7-5 mcg/g cr), metanephrine 4095 (21–153 mcg/g cr), normetanephrine 3920 (108–524 mcg/g cr). CT abdomen showed 3.8 cm mass in the left adrenal gland with enhancing walls and central hypoattenuation and a normal contralateral adrenal gland. MR brain showed a partial empty sella without any mass. 123I-metaiodobenzylguanidine scintigraphy showed uptake in the left adrenal mass. Once cortisol was reduced to <25 ug/dL, she was transitioned from etomidate to metyrapone; alpha-methyltyrosine and prazosin was also begun. Following left laparoscopic adrenalectomy, ACTH decreased to <5 pg/mL confirming that the pheochromocytoma was the source of ectopic Cushing’s. Gross examination of the mass was notable for a spongy, tan, roughly spherical medullary neoplasm (3 cm in diameter) with a rim of brown and focally yellow adrenal cortex up to 4 mm thick. Marked diffuse adrenal cortical hyperplasia was noted. The tumor showed varied growth patterns, including solid areas and spongy, angioma-like areas with prominent small blood vessels. Immunohistochemical staining was positive for somatostatin receptor 2A, tyrosine hydroxylase and ACTH in tumor cells and negative for T-PIT. She was discharged on replacement hydrocortisone therapy, minimal insulin for diabetes and has shown substantial clinical improvement. Cushing’s syndrome due to ectopic ACTH-producing pheochromocytoma is rare. Worsening hyperglycemia in the presence of hypertension, even without typical clinical findings of Cushing’s, should prompt further hormonal work up. The absence of the transcription factor TPIT, which is a lineage determinant for pituitary corticotrophs, suggests that novel pathways are involved in differentiation of cells that produce ectopic ACTH.


2019 ◽  
Vol 14 (8) ◽  
pp. 1027-1030 ◽  
Author(s):  
Meltem Özdemir ◽  
Rasime Pelin Kavak ◽  
Engin Dinç

PEDIATRICS ◽  
1976 ◽  
Vol 58 (3) ◽  
pp. 412-422
Author(s):  
Dan C. Moore ◽  
Diana S. Tattoni ◽  
George A. Limbeck ◽  
R. H.A. Ruvelcaba ◽  
Diana S. Lindner ◽  
...  

A total of 130 patients with uncomplicated short stature (4 to 17 years of age) were treated with oxandrolone, 0.25 mg/kg/day, for up to four years. Oxandrolone therapy resulted in a two-fold increase in mean growth velocity in the first six months of therapy and was an effective growth stimulant for the full four-year period. There was no overall adverse effect of oxandrolone on post-treatment mean growth velocity or on skeletal maturation relative to height gain. There were 37 patients with greater increase in height age than bone age and 22 patients with greater increase in bone age than height age. Assessment of the contribution of oxandrolone therapy to the latter group is difficult because of inadequate methodology and the wide variation in individual growth patterns. Taken in their entirety, the data suggest that oxandrolone is useful in the prolonged treatment of uncomplicated short stature and is not associated with undesirable acceleration of skeletal maturation.


2020 ◽  
Vol 4 (4) ◽  
pp. 281-289 ◽  
Author(s):  
Andy Tsai ◽  
Patrick R Johnston ◽  
Leslie B Gordon ◽  
Michele Walters ◽  
Monica Kleinman ◽  
...  

2021 ◽  
Vol 26 (2) ◽  
Author(s):  
Fernando Penteado Lopes da SILVA

ABSTRACT The Herbst appliance can be very effective in treatment of Class II patients with mandibular retrognathism. Because of the continuous action in a full-time basis, treatment time using it normally takes from six to ten months, and is usually followed by a second phase of full fixed appliances, in order to obtain both occlusal refinement and long term stability. Despite Herbst appliance’s effectiveness in the occlusal and dentoalveolar perspectives, its facial results may differ among patients with different growth patterns, as well as in distinct stages of skeletal maturation. In the current paper, two patients with different facial patterns are presented, who were treated under the same protocol, using Herbst and full fixed appliances in different skeletal maturation stages, and both dentoalveolar and facial results are compared and discussed.


Sign in / Sign up

Export Citation Format

Share Document